Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with Leman Biotech Co., Ltd, a clinical-stage immune-metabolism drug developer based in Shenzhen. The collaboration aims to explore the application and translation capabilities of immune metabolism reprogramming technology (Meta 10) in solid tumor CAR-T therapy, with a focus on solid tumor treatment and the joint promotion of the cell therapy industry. Financial details of the partnership were not disclosed.
Kati Med’s CAR-T Pipeline and Leman Bio’s Metabolic Enhanced CAR-T Therapy
Kati Med boasts a chimeric-antigen receptor (CAR)-T product pipeline, with KT032 currently in clinical trials in China for the treatment of advanced ovarian cancer. This pipeline highlights the company’s commitment to advancing CAR-T therapies for cancer patients. Meanwhile, Leman Bio is developing a CD19-targeted metabolic enhanced CAR-T therapy, which has reportedly clinically cured three patients at extremely low dosages in a Phase III study, according to the source.
Joint Efforts in Cell Therapy Industry Development
The partnership between Kati Medical and Leman Biotech underscores the potential of immune metabolism reprogramming technology in enhancing the efficacy of CAR-T therapies for solid tumors. By combining their expertise and resources, the two companies aim to contribute significantly to the development of the cell therapy industry, offering new hope for patients with solid tumors.-Fineline Info & Tech
